COVID-19, Post-acute COVID-19 Syndrome
Conditions
Keywords
COVID-19, Post-acute COVID-19 Syndrome, Coagulopathy, Fibrinolysis, Thrombosis
Brief summary
The present study aims at assessing long-term hemostatic profile of patients recovered from COVID-19 acute infection that remain asymptomatic (POST-COVID) versus patients with residual symptoms (LONG-COVID) through the employment of a commercially available new generation point-of-care viscoelastic device. The primary endpoint is based upon the hypothesis that patients with residual symptoms maintain an abnormal coagulation profile even after recovery from COVID-19.
Interventions
DIAGNOSTIC_TESTClotPro assessment
Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)
DIAGNOSTIC_TESTLaboratory analysis
Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)
OTHERInterview
Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
Sponsors
IRCCS Policlinico S. Donato
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age \> 18 years; * recovery from acute COVID-19 infection; * COVID-19 pneumonia that required hospitalization in our Institution; * discharge from the hospital minimum 3 months before the day of the visit; * written consent to participate to the study.
Exclusion criteria
* none.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ClotPro EXTEST | Day of the visit | Extrinsic pathway of the coagulation as measured by the ClotPro (coagulation time CT, seconds; maximum clot firmness, MCF, millimeters) |
| ClotPro INTEST | Day of the visit | Intrinsic pathway of the coagulation as measured by the ClotPro (coagulation time CT, seconds; maximum clot firmness, MCF, millimeters) |
| ClotPro FIBTEST | Day of the visit | Fibrinogen contribution to the overall clot strength as measured by the ClotPro (maximum clot firmness, MCF, millimeters) |
| ClotPro TPATEST | Day of the visit | Resistance to the fibrinolysis induced by the tPA (tissue plasminogen) as measured by the ClotPro (lysis time, LT, seconds; maximum lysis, ML, %). |
Countries
Italy
Outcome results
None listed